Zhongsheng Pharmaceutical (01177) is now up more than 5%. As of press release, it has risen 4.7% to HK$2.45, with a turnover of HK$27.146,500.
The Zhitong Finance App learned that Zhongsheng Pharmaceutical (01177) is now up more than 5%. As of press release, it has risen 4.7% to HK$2.45, with a turnover of HK$27.1465 million.
According to the news, China Biopharmaceutical announced that the key registered clinical study of the Class 1 innovative drug lovaxitinib tablets “Rovadicitinib (TQ05105)” independently developed by the Group for the treatment of medium- and high-risk myelofibrosis has reached the main end. The Group has communicated with the Drug Evaluation Center (CDE) of the China National Drug Administration on the marketing application for TQ05105 tablets and obtained the CDE's approval to submit the marketing application for this product. The Group will submit a listing application for TQ05105 in the near future.
HSBC previously released a research report stating that Zhongsheng Pharmaceuticals and Boehringer Ingelheim are cooperating to develop three assets in the clinical development stage and several early clinical assets in China. The bank believes that this reflects the high recognition of Zhongsheng Pharmaceuticals' commercial capabilities by multinational companies. The bank believes that the three assets have first-class potential and have a synergy effect with the Group's existing product line. The bank expects the three assets Brigimadlin, Zongertinib, and BI-764532 to be listed in China in 2025, 2027, and 2028, respectively, and reach a sales peak of 50 billion yuan in 2030. HSBC expects that Zhongsheng Pharmaceuticals will continue to grow, supported by the launch of new drugs and impressive business prospects.